Johnson & Johnson (NYSE:JNJ) Shares Down 0.5% on Analyst Downgrade

Shares of Johnson & Johnson (NYSE:JNJ - Get Free Report) traded down 0.5% during mid-day trading on Monday after Barclays lowered their price target on the stock from $160.00 to $159.00. Barclays currently has an equal weight rating on the stock. Johnson & Johnson traded as low as $146.61 and last traded at $147.03. 10,678,393 shares traded hands during mid-day trading, an increase of 55% from the average session volume of 6,880,262 shares. The stock had previously closed at $147.77.

Other equities analysts have also recently issued research reports about the company. Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price objective for the company. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Royal Bank of Canada raised their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research note on Wednesday, October 16th. Finally, Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $173.27.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company's stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of JNJ. Summit Wealth Partners LLC raised its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock valued at $1,463,000 after acquiring an additional 61 shares during the last quarter. Powers Advisory Group LLC grew its stake in shares of Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after purchasing an additional 61 shares during the period. Eagle Wealth Strategies LLC lifted its stake in Johnson & Johnson by 2.8% in the third quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock valued at $372,000 after buying an additional 63 shares during the period. Knuff & Co LLC boosted its holdings in Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock worth $1,534,000 after buying an additional 64 shares during the last quarter. Finally, Perkins Coie Trust Co grew its position in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Perkins Coie Trust Co now owns 3,705 shares of the company's stock worth $600,000 after buying an additional 65 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.7 %

The business has a 50 day moving average price of $148.35 and a 200 day moving average price of $156.11. The company has a market capitalization of $356.57 billion, a P/E ratio of 21.43, a PEG ratio of 2.39 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.35%. Johnson & Johnson's dividend payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.